Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C7H8N4O2.C6H14N2O2 |
Molecular Weight | 326.3516 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCCC[C@H](N)C(O)=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O
InChI
InChIKey=UBLVUWUKNHKCJJ-ZSCHJXSPSA-N
InChI=1S/C7H8N4O2.C6H14N2O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;7-4-2-1-3-5(8)6(9)10/h3H,1-2H3,(H,8,9);5H,1-4,7-8H2,(H,9,10)/t;5-/m.0/s1
Molecular Formula | C6H14N2O2 |
Molecular Weight | 146.1876 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C7H8N4O2 |
Molecular Weight | 180.164 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9676340 | https://www.ncbi.nlm.nih.gov/pubmed/27713276
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9676340 | https://www.ncbi.nlm.nih.gov/pubmed/27713276
Since its discovery as component of the tea leaf by Albert Kossel in 1888, the history of theophylline (CAS 58-55-9) has been a long and successful one. At the turn of the century, theophylline became less expensive due to chemical synthesis and was primarily used as diuretic in subsequent years. It was Samuel Hirsch who discovered the bronchospasmolytic effect of theophylline in 1992, however, despite this pioneering discovery theophylline continued to be used primarily as diuretic and cardiac remedy. The molecular mechanism of bronchodilatation is inhibition of phosphodiesterase(PDE)3 and PDE4, but the anti-inflammatory effect may be due to histone deacetylase (HDAC) activation, resulting in switching off of activated inflammatory genes.
Theophylline is indicated for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9676340
Curator's Comment: Albert Kossel discovered theophylline as a component of the tea leaf
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094125 |
|||
Target ID: CHEMBL2093863 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER Approved UseTheophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. Launch Date1982 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7332727/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
THEOPHYLLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
95.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7332727/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
THEOPHYLLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.51 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7332727/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
THEOPHYLLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
41% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7332727/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
THEOPHYLLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg/mL steady, intravenous Highest studied dose Dose: 20 mg/mL Route: intravenous Route: steady Dose: 20 mg/mL Sources: Page: p.500 |
unhealthy, 39 years (51 % < 40 years) n = 87 Health Status: unhealthy Condition: COPD|asthma Age Group: 39 years (51 % < 40 years) Sex: M+F Population Size: 87 Sources: Page: p.500 |
Disc. AE: Vomiting... Other AEs: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (grade 3, 5.75%) Other AEs:Vomiting (12.64%) Sources: Page: p.500 |
1200 mg 1 times / day steady, oral Recommended Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: Page: p.149 |
unhealthy, 66 ± 9 n = 6 Health Status: unhealthy Condition: COPD Age Group: 66 ± 9 Sex: M+F Population Size: 6 Sources: Page: p.149 |
Disc. AE: Gastrointestinal discomfort, Supraventricular tachycardia... Other AEs: Tremor, Nervousness... AEs leading to discontinuation/dose reduction: Gastrointestinal discomfort (grade 3, 16.7%) Other AEs:Supraventricular tachycardia (grade 3, 16.7%) Tremor (16.7%) Sources: Page: p.149Nervousness (16.7%) Dysrhythmias (grade 1, 16.7%) |
800 mg single, oral Recommended Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: Page: p.146 |
unhealthy, 66 ± 9 n = 6 Health Status: unhealthy Condition: COPD Age Group: 66 ± 9 Sex: M Population Size: 6 Sources: Page: p.146 |
|
800 mg 1 times / day steady, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: steady Dose: 800 mg, 1 times / day Sources: Page: p.148 |
unhealthy, 66 ± 9 n = 16 Health Status: unhealthy Condition: COPD Age Group: 66 ± 9 Sex: M+F Population Size: 16 Sources: Page: p.148 |
|
1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
Other AEs: Generalized epileptic seizure, Cardiac arrhythmias... Other AEs: Generalized epileptic seizure (grade 4-5) Sources: Cardiac arrhythmias (grade 4-5) Calcium increased serum Creatine kinase increased Blood myoglobin increased Leukocyte count increased Serum phosphate decreased Magnesium serum decreased Acute myocardial infarction Obstructive uropathy Cardio-respiratory arrest (grade 5) Hypoxic encephalopathy (grade 5) |
1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Other AEs: Vomiting, Abdominal pain... Other AEs: Vomiting (61%) Sources: Abdominal pain (12%) Diarrhea (14%) Hematemesis (2%) Hypokalemia (43%) Acid-base balance abnoraml (9%) Sinus tachycardia (62%) Supraventricular tachycardia (14%) Premature ventricular ectopic beats (19%) Hypotension (8%) Nervousness (21%) Tremor (14%) Disorientation (11%) Seizures (5%) |
1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Other AEs: Vomiting, Hypokalemia... Other AEs: Vomiting (30%) Sources: Hypokalemia (44%) Hyperglycemia (18%) Acid-base balance abnoraml (9%) Sinus tachycardia (100%) Supraventricular tachycardia (12%) Premature ventricular ectopic beats (10%) Atrial flutter/ fibrillation (12%) Multifocal atrial tachycardia (2%) Hemodynamic instability (40%) Tremor (16%) Seizures (14%) |
10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 14 Health Status: unknown Population Size: 14 Sources: |
Other AEs: Abdominal pain, Rhabdomyolysis... Other AEs: Abdominal pain (21%) Sources: Rhabdomyolysis (7%) Hypotension (21%) Nervousness (64%) Disorientation (7%) |
10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Other AEs: Vomiting, Hypokalemia... Other AEs: Vomiting (73%) Sources: Hypokalemia (85%) Hyperglycemia (98%) Acid-base balance abnoraml (34%) Sinus tachycardia (100%) Supraventricular tachycardia (2%) Premature ventricular ectopic beats (3%) Atrial flutter/ fibrillation (1%) Hemodynamic instability (7%) Tremor (38%) Seizures (5%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vomiting | 12.64% | 20 mg/mL steady, intravenous Highest studied dose Dose: 20 mg/mL Route: intravenous Route: steady Dose: 20 mg/mL Sources: Page: p.500 |
unhealthy, 39 years (51 % < 40 years) n = 87 Health Status: unhealthy Condition: COPD|asthma Age Group: 39 years (51 % < 40 years) Sex: M+F Population Size: 87 Sources: Page: p.500 |
Vomiting | grade 3, 5.75% Disc. AE |
20 mg/mL steady, intravenous Highest studied dose Dose: 20 mg/mL Route: intravenous Route: steady Dose: 20 mg/mL Sources: Page: p.500 |
unhealthy, 39 years (51 % < 40 years) n = 87 Health Status: unhealthy Condition: COPD|asthma Age Group: 39 years (51 % < 40 years) Sex: M+F Population Size: 87 Sources: Page: p.500 |
Nervousness | 16.7% | 1200 mg 1 times / day steady, oral Recommended Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: Page: p.149 |
unhealthy, 66 ± 9 n = 6 Health Status: unhealthy Condition: COPD Age Group: 66 ± 9 Sex: M+F Population Size: 6 Sources: Page: p.149 |
Tremor | 16.7% | 1200 mg 1 times / day steady, oral Recommended Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: Page: p.149 |
unhealthy, 66 ± 9 n = 6 Health Status: unhealthy Condition: COPD Age Group: 66 ± 9 Sex: M+F Population Size: 6 Sources: Page: p.149 |
Dysrhythmias | grade 1, 16.7% | 1200 mg 1 times / day steady, oral Recommended Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: Page: p.149 |
unhealthy, 66 ± 9 n = 6 Health Status: unhealthy Condition: COPD Age Group: 66 ± 9 Sex: M+F Population Size: 6 Sources: Page: p.149 |
Gastrointestinal discomfort | grade 3, 16.7% Disc. AE |
1200 mg 1 times / day steady, oral Recommended Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: Page: p.149 |
unhealthy, 66 ± 9 n = 6 Health Status: unhealthy Condition: COPD Age Group: 66 ± 9 Sex: M+F Population Size: 6 Sources: Page: p.149 |
Supraventricular tachycardia | grade 3, 16.7% Disc. AE |
1200 mg 1 times / day steady, oral Recommended Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: Page: p.149 |
unhealthy, 66 ± 9 n = 6 Health Status: unhealthy Condition: COPD Age Group: 66 ± 9 Sex: M+F Population Size: 6 Sources: Page: p.149 |
Acute myocardial infarction | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
|
Blood myoglobin increased | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
|
Calcium increased serum | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
|
Creatine kinase increased | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
|
Leukocyte count increased | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
|
Magnesium serum decreased | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
|
Obstructive uropathy | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
|
Serum phosphate decreased | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
|
Cardiac arrhythmias | grade 4-5 | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
Generalized epileptic seizure | grade 4-5 | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
Cardio-respiratory arrest | grade 5 | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
Hypoxic encephalopathy | grade 5 | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
Disorientation | 11% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Abdominal pain | 12% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Diarrhea | 14% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Supraventricular tachycardia | 14% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Tremor | 14% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Premature ventricular ectopic beats | 19% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Hematemesis | 2% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Nervousness | 21% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Hypokalemia | 43% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Seizures | 5% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Vomiting | 61% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Sinus tachycardia | 62% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Hypotension | 8% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Acid-base balance abnoraml | 9% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Premature ventricular ectopic beats | 10% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Sinus tachycardia | 100% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Atrial flutter/ fibrillation | 12% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Supraventricular tachycardia | 12% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Seizures | 14% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Tremor | 16% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Hyperglycemia | 18% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Multifocal atrial tachycardia | 2% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Vomiting | 30% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Hemodynamic instability | 40% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Hypokalemia | 44% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Acid-base balance abnoraml | 9% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Abdominal pain | 21% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 14 Health Status: unknown Population Size: 14 Sources: |
Hypotension | 21% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 14 Health Status: unknown Population Size: 14 Sources: |
Nervousness | 64% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 14 Health Status: unknown Population Size: 14 Sources: |
Disorientation | 7% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 14 Health Status: unknown Population Size: 14 Sources: |
Rhabdomyolysis | 7% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 14 Health Status: unknown Population Size: 14 Sources: |
Atrial flutter/ fibrillation | 1% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Sinus tachycardia | 100% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Supraventricular tachycardia | 2% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Premature ventricular ectopic beats | 3% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Acid-base balance abnoraml | 34% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Tremor | 38% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Seizures | 5% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Hemodynamic instability | 7% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Vomiting | 73% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Hypokalemia | 85% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Hyperglycemia | 98% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[The effect of GM-CSF on endothelin-1 and endothelin converting enzyme gene expression in human airway smooth muscle cells with or without theophylline incubation]. | 1997 Oct |
|
[A case of acute renal failure with rhabdomyolysis caused by the interaction of theophylline and clarithromycin]. | 1999 Jun |
|
Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-Ht4 or 5-Ht6 receptors following antipsychotic administration. | 1999 Mar |
|
Effects of theophylline, dexamethasone and salbutamol on cytokine gene expression in human peripheral blood CD4+ T-cells. | 1999 Nov |
|
[A case of acute theophylline intoxication with repeated status convulsivus]. | 1999 Nov |
|
Theophylline as a therapy for chronic lymphocytic leukemia: a case report and review of literature. | 2000 |
|
Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders. | 2000 Apr |
|
Effects of theophylline on human eosinophil functions: comparative study with neutrophil functions. | 2000 Aug |
|
Steroid hormone activity of flavonoids and related compounds. | 2000 Jul |
|
[Depression of serum pyridoxal levels in theophylline-related seizures]. | 2000 Jul |
|
Theophylline administration markedly reduces hepatic and pulmonary implantation of B16-F10 melanoma cells in mice. | 2000 Oct |
|
Computerised advice on drug dosage to improve prescribing practice. | 2001 |
|
Treatment options for sleep apnoea. | 2001 |
|
A comparison of reflectance and transmittance near-infrared spectroscopic techniques in determining drug content in intact tablets. | 2001 |
|
A novel method for measuring gel strength of controlled release hydrogel tablets using a cone/plate rheometer. | 2001 |
|
Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs. | 2001 Apr |
|
How to safeguard delivery of high-alert i.v. drugs. | 2001 Feb |
|
High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. V. Validation of a direct injection/on-line guard cartridge extraction--tandem mass spectrometry method for CYP1A2 inhibition assessment. | 2001 Feb |
|
Rapid modulation of Na+/K+-ATPase activity in osmoregulatory tissues of a salmonid fish. | 2001 Feb |
|
Screening of beta-2 agonists and confirmation of fenoterol, orciprenaline, reproterol and terbutaline with gas chromatography-mass spectrometry as tetrahydroisoquinoline derivatives. | 2001 Feb 10 |
|
Determination of urinary methylated purine pattern by high-performance liquid chromatography. | 2001 Feb 10 |
|
Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. | 2001 Feb 15 |
|
Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis. | 2001 Jan |
|
Relationships between lipolysis induced by various lipolytic agents and hormone-sensitive lipase in rat fat cells. | 2001 Jan |
|
Calculation of the dimensions of dosage forms with release controlled by diffusion for in vivo use. | 2001 Jan |
|
[Rhabdomyolysis as a rare complication of theophylline poisoning]. | 2001 Jan 15 |
|
Suspected caffeine and ephedrine toxicosis resulting from ingestion of an herbal supplement containing guarana and ma huang in dogs: 47 cases (1997-1999). | 2001 Jan 15 |
|
Mice with a deletion in the gene for CCAAT/enhancer-binding protein beta have an attenuated response to cAMP and impaired carbohydrate metabolism. | 2001 Jan 5 |
|
Newer and alternative non-steroidal treatments for asthmatic inflammation. | 2001 Jan-Feb |
|
Improvement of encapsulation efficiency of water-in-oil-in-water emulsion with hypertonic inner aqueous phase. | 2001 Jan-Feb |
|
Adenosine diphosphate ribose dilates bovine coronary small arteries through apyrase- and 5'-nucleotidase-mediated metabolism. | 2001 Jan-Feb |
|
Drug treatment of airway inflammation in asthma. | 2001 Mar |
|
Refractory seizure with hypokalaemia. | 2001 Mar |
|
Purinergic contribution to circulatory, metabolic, and adrenergic responses to acute hypoxemia in fetal sheep. | 2001 Mar |
|
Adenosine induces initial hypoxic-ischemic depression of synaptic transmission in the rat hippocampus in vivo. | 2001 Mar |
|
Alkylxanthine-induced recovery of respiratory function following cervical spinal cord injury in adult rats. | 2001 Mar |
|
Profile of moxifloxacin drug interactions. | 2001 Mar 15 |
|
Inhibitory effect of theophylline on recombinant GABA(A) receptor. | 2001 Mar 5 |
|
Cytosolic xanthine oxidoreductase mediated bioactivation of ethanol to acetaldehyde and free radicals in rat breast tissue. Its potential role in alcohol-promoted mammary cancer. | 2001 Mar 7 |
Patents
Sample Use Guides
For a given population there is no single theophylline dose that will provide both safe
and effective serum concentrations for all patients. The dose of theophylline must be individualized on the basis of serum theophylline concentration measurements in order to achieve a dose that will provide maximum potential benefit with minimal risk of adverse effects.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24231152
1 mM theophylline inhibited histamine release from human skin mast cells
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:08:32 GMT 2023
by
admin
on
Fri Dec 15 18:08:32 GMT 2023
|
Record UNII |
O196W99W6K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID40100407
Created by
admin on Fri Dec 15 18:08:32 GMT 2023 , Edited by admin on Fri Dec 15 18:08:32 GMT 2023
|
PRIMARY | |||
|
134381
Created by
admin on Fri Dec 15 18:08:32 GMT 2023 , Edited by admin on Fri Dec 15 18:08:32 GMT 2023
|
PRIMARY | |||
|
85531-28-8
Created by
admin on Fri Dec 15 18:08:32 GMT 2023 , Edited by admin on Fri Dec 15 18:08:32 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
m10706
Created by
admin on Fri Dec 15 18:08:32 GMT 2023 , Edited by admin on Fri Dec 15 18:08:32 GMT 2023
|
PRIMARY | Merck Index | ||
|
O196W99W6K
Created by
admin on Fri Dec 15 18:08:32 GMT 2023 , Edited by admin on Fri Dec 15 18:08:32 GMT 2023
|
PRIMARY | |||
|
281-314-7
Created by
admin on Fri Dec 15 18:08:32 GMT 2023 , Edited by admin on Fri Dec 15 18:08:32 GMT 2023
|
PRIMARY | |||
|
83920-54-1
Created by
admin on Fri Dec 15 18:08:32 GMT 2023 , Edited by admin on Fri Dec 15 18:08:32 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |